Skip to content
Screener

Upstream Bio, Inc. UPB Price / book

Price / book at other companies

Amgen logo
AmgenAMGN
16.7×-3.4×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
2.1×+0.2×
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
5.9×+4.7×
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
3.1×+2.3×
Savara logo
SavaraSVRA
8.8×+5.5×
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
125.1×+108×

Other financials

Income statement

See full
Revenue$773.0K-17.5%
Operating income-$42.4M+4.5%
Net income-$39.7M+0.7%
EPS (diluted)-$0.73+1.4%

Balance sheet

See full
Cash & equivalents$79.4M+74.7%
Total debt$954.0K-38.9%
Total equity$271.0M-33.7%
Total assets$281.2M-33.1%

Cash flow

See full
Operating cash flow-$35.6M+9.2%
CapEx$54.0K-70.8%
Free cash flow-$30.7M-55.0%

Valuation

See full
Market cap$394.54M-54.7%
Enterprise value$316.1M-61.6%
P/S124.9×-195×

Profitability

See full
Operating margin-5,382.6%+1,393pp
Net margin-4,955.7%+2,041pp

Returns & leverage

See full
Return on equity-46%—
Debt / equity0×0.0×
Current ratio28×-10.3×

Where this comes from

Calculated from Upstream Bio, Inc.’s reported figures.

market cap/total stockholders equity=1.4×

Based on the most recent quarter.

The source filing: Upstream Bio, Inc.’s 10-Q, filed August 11, 2026. Open the filing →

Filed
Aug 11, 2026, 7:10 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-343417

FAQ

What is Upstream Bio, Inc.'s price / book?
Upstream Bio, Inc. (UPB) reported price / book of 1.4× in Q2 2026.
How has Upstream Bio, Inc.'s price / book changed year-over-year?
Upstream Bio, Inc.'s price / book decreased by 7.3% year-over-year, from 1.5× to 1.4×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.

Ask your AI about Upstream Bio, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude